Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 250Carcinoma, Non-Small-Cell Lung 86Carcinoma, Renal Cell 62Neoplasm Metastasis 53Neoplasms 51Prostatic Neoplasms 35Lung Neoplasms 32Uveal Melanoma 29Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Brain Neoplasms 24Colorectal Neoplasms 23Sarcoma 22Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Kidney Neoplasms 18Skin Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Urinary Bladder Neoplasms 14Triple Negative Breast Neoplasms 14Mesothelioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Recurrence 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

pembrolizumab 1Sirolimus 1Nivolumab 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Cancers × Ipilimumab × Clear all
NCT03956680 2025-02-19

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Bristol-Myers Squibb

Phase 1 Completed
54 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡